<DOC>
	<DOCNO>NCT00171509</DOCNO>
	<brief_summary>The purpose study determine whether cyclosporine microemulsion give day instead twice day benefit kidney function , blood pressure , lipid profile glucose control stable liver transplant recipient . The study also aim identify target range level cyclosporine microemulsion blood .</brief_summary>
	<brief_title>Efficacy Safety Cyclosporine Microemulsion Given Once Day Adult Stable Liver Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>At least 6 month posttransplant At least one following : stable deteriorate kidney function , high blood pressure , high lipid , high glucose Receiving stable dos cyclosporine microemulsion past 3 month Severe rejection within past 3 month Severe kidney dysfunction Transplanted hepatitis C autoimmune hepatitis Other protocoldefined exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Liver transplant , adult , day administration , Immunosuppressants</keyword>
</DOC>